(Date:11/4/2009)...wire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE ), a...etrics software, today reported financial results ... ,, Michael Tzannes, Aware,s Chairman and Chief...nced an agreement to sell our DSL and home network...ductor company being spun out of Infineon. This t...
(Date:11/4/2009)...-FirstCall/ -- BIO-key International, Inc. (OTC Bu...etric identification software is showcasing donor ...nference being held at the New Orleans Convention ...de hands-on product demonstrations of its state-of...Also, at 5 PM on Monday, October 26, Peter Lux, ma...
(Date:11/4/2009)...swire/ -- GenVault Corporation (Carlsbad, CA) toda...oined its Board of Directors. Dr. Brody, the Irwi... is an acclaimed physician-scientist and universit.... Brody served as president of The Johns Hopkins U... of Engineering and the Institute of Medicine, and...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7BIO-key(R) International Exhibiting at AABB TXPO 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases 28HTDS 29 57763 1Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases 28HTDS 29 57763 2ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 1ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 2ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 3Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 1Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 2Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 3Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 14176 4(Date:11/6/2009).... 6 ,, 3Q09 Corpor...enza(TM) E.U. Marketing Authorization to Astellas ...commercial readiness activities Expanded manageme...eting; and Director, Commercial Operations Appoin...udit Committee chairman , Upcoming 2009 Mil...
(Date:11/6/2009)...6 Intarcia Therapeutics, Inc. deli...OS® continuous delivery of exenatide) program... Annual Diabetes Technology Meeting in San Francis...in/prnh/20050301/SFTU126LOGO ) ,, Continuous ...wers Plasma Glucose, HbA1c and Reduces Weight in a...
(Date:11/5/2009).... 5 GenVec, Inc. (Nasdaq...r the third quarter ended September 30, 2009. GenV...share) for the three months ended September 30, 20...er share) in the comparable quarter of 2008. For t...net loss was $14.1 million ($0.15 per share), comp...
(Date:11/5/2009)...ewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bullet...cer, President and CEO of Imagenetix, will be pres...CRO Conference on Thursday, December 3rd, at 10:30...bout LD MICRO ,, LD MICRO is a by-invitation on...lued companies in the micro-cap space. Since 2002,...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2... Cell Biosciences, Inc., a,provider of nanoproteo...today,announced the launch of its first kits for t...y(TM) 3000 Protein Analysis System. The new kits a...he MEK and ERK families, which,play critical roles...evelopers,have targeted signaling via MEK and ERK ...
...ed Decision Support in Diabetes Drug Therapy , , ...shown statistically significant associations of ce...y mass index (BMI) and edema (fluid retention) in ...pioglitazone and rosiglitazone. The study, co-auth...r Affiliate at The Hospital of Central Connecticut...
...ic, a division of Simbionix USA,Corporation (Simbi...ducts and,technology for training medical salespeo.... Williams joined the company as Sales Executive f...out of a new office located in,Grayslake, Illinois...rning technologies and medical,procedures. His pri...
Other Biology Technology:Cell Biosciences Introduces Kits for Oncoprotein Analysis 2Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study 2Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office 2... with HRP conjugated rabbit polyclonal detection a... coating antibody. • BUF040A contains rab...ding between the coating and detection antibodies....ewly conjugated antibodies, to reconstitute lyophi...
...el piece, we can identify it using MALDI-TOF/TOF m...duce a mixture of peptides. The molecular weights ..., and the amino acid sequences of the top 10 peaks...ALDI-TOF/TOF. The masses and sequences will be use...
OmniSlide Heated Wash Module from Thermo Scientific
Factor Xa Protease from QIAGEN
Biology Products: